Welcome to ProbeChem!Global Supplier of Chemical Probes, Inhibitors & Agonists.
Chemical Structure : T-025
CAS No.: 2407433-00-3
Catalog No.: PC-35047Not For Human Use, Lab Use Only.
T-025 (T025, CLK inhibitor T-025) is an orally available, potent inhibitor of Cdc2-like kinases (CLKs) with Kd of 4.8, 0.096, 6.5, and 0.61 nM for CLK1, CLK2, CLK3, and CLK4, also inhibits DYRK1A and DYRK1B with IC50 of 0.074 and 1.5 nM.
| Packing | Price | Stock | Quantity |
|---|---|---|---|
| 2 mg | $198 | In stock | |
| 5 mg | $298 | In stock | |
| 10 mg | $458 | In stock | |
| 25 mg | $758 | In stock | |
| 50 mg | Get quote | ||
| 100 mg | Get quote |
Bulk size, bulk discount!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
T-025 (T025, CLK inhibitor T-025) is an orally available, potent inhibitor of Cdc2-like kinases (CLKs) with Kd of 4.8, 0.096, 6.5, and 0.61 nM for CLK1, CLK2, CLK3, and CLK4, also inhibits DYRK1A and DYRK1B with IC50 of 0.074 and 1.5 nM.
T-025 (T025, CLK inhibitor T-025) reduces CLK-dependent phosphorylation, induces skipping exon, resulting in anti-proliferative effect in MDA-MB-468 in vitro and in vivo accompanied by the modulation of pre-mRNA splicing.
T-025 (T025, CLK inhibitor T-025) shows sensitivity against high CLK2 expression or MYC amplification cancer celles.
T-025 (T025, CLK inhibitor T-025) exhibits significant anti-tumor efficacy in MYC-driven breast tumor allograft models.
| M.Wt | 382.431 | |
| Formula | C21H18N8 | |
| Appearance | Solid | |
| Storage |
|
|
| Solubility |
10 mM in DMSO |
|
| Chemical Name/SMILES |
N2-methyl-N4-(pyrimidin-2-ylmethyl)-5-(quinolin-6-yl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine |
|
1. Iwai K, et al. EMBO Mol Med. 2018 May 16. pii: e8289.
Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright
